Renaissance Technologies LLC Lowers Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Renaissance Technologies LLC trimmed its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 16.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,604 shares of the company’s stock after selling 17,100 shares during the quarter. Renaissance Technologies LLC owned 0.30% of Dianthus Therapeutics worth $2,293,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of DNTH. Vestal Point Capital LP acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter worth $1,404,000. Octagon Capital Advisors LP increased its holdings in Dianthus Therapeutics by 15.4% in the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock valued at $5,762,000 after purchasing an additional 74,000 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in Dianthus Therapeutics in the first quarter valued at about $630,000. Vanguard Group Inc. lifted its stake in shares of Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares in the last quarter. Finally, StemPoint Capital LP acquired a new position in shares of Dianthus Therapeutics during the first quarter worth about $1,304,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock opened at $27.88 on Wednesday. Dianthus Therapeutics, Inc. has a 1-year low of $6.58 and a 1-year high of $33.77. The company has a market capitalization of $818.25 million, a P/E ratio of -4.78 and a beta of 1.85. The business’s fifty day moving average price is $27.90 and its two-hundred day moving average price is $26.20.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on DNTH. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Thursday, September 26th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock. Finally, Wedbush decreased their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $44.71.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.